Endometrial CancerNCT00166985
The Role of Functional MRI and Doppler Sonography in Assessing Blood Vessel Formation Within the Tumors of Endometrial Cancer Patients
An observational study of Endometrial Cancer, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Adenocarcinoma of the endometrium is the fourth most frequent cancer in women. Surgery is the treatment of choice in patients with noninvasive or locally advanced disease. The surgical technique consists of an exploratory laparotomy, with total hysterectomy, bilateral oophorectomy, peritoneal washing, and, in selected… Read more about this study
- Who is it for?
- Ages 18 to 80 years, women only
- Conditions the study is for
- Endometrial Cancer
- How many people
- 200 participants
- Where
- 1 siteTaiwan
- Study dates
- Sep 2004to Dec 2008
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Endometrial cancer patients with histopathologic proof who are arranged to receive staging surgery.
- All of the patients who will be enrolled into this study need to sign the consent form and the study protocol will be under the approval of the Institutional Review Board of the patient's hospital.
Who cannot join
- Tumors of histologic types other than adenocarcinoma and adenoacanthoma will be excluded.
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
National Taiwan University Hospital
Taipei
Chi-An Chen, MD, 886-2-2312-3456 ext. 5157, cachen@ha.mc.ntu.edu.tw
About this study
Official title: The Role of Functional MRI and Doppler Sonography in Assessing Intratumoral Angiogenesis of Endometrial Cancer Patients
Adenocarcinoma of the endometrium is the fourth most frequent cancer in women. Surgery is the treatment of choice in patients with noninvasive or locally advanced disease. The surgical technique consists of an exploratory laparotomy, with total hysterectomy, bilateral oophorectomy, peritoneal washing, and, in selected high-risk patients, omental and peritoneal biopsies and lymphadenectomy. Therefore, preoperative clinical and instrumental staging of the local spread of disease, as well as local and distant lymph node involvement, represent a critical step in tailoring the extent and the radicalness of surgery.
The role of angiogenesis in cancer growth and metastasis has been gaining much attention for decades. Recent clinical evidence supports this notion. The gradual increase in angiogenesis intensity with tumor progression in malignant melanoma has been reported. Abulafia et al. reported that increasing angiogenicity could be noted from simple hyperplasia, complex hyperplasia, atypical hyperplasia, and Stage IA endometrial carcinoma to invasive endometrial carcinoma. The investigators' research team has shown that incremental angiogenesis could be demonstrated in the tumorigenesis and the possibility of lymph node metastasis in endometrial malignancy. Besides, other growth factors such as vascular endothelial growth factor (VEGF), transforming growth factor- (TGF-), IL-6 and IL-8 have also been reported to correlate with the angiogenesis and the metastasis of endometrial cancer. It seems that tumor angiogenesis of endometrial cancer could be utilized as an important parameter to assess the disease severity of the endometrial cancer.
So, the investigators would like to propose this proposal to focus on the tumor angiogenesis in endometrial cancer patients. There are several purposes in this study. First, the investigators will evaluate and compare tumor angiogenesis surveyed from functional MRI and power Doppler sonography in endometrial cancer patients who receive surgery. Second, the investigators will evaluate whether tumor angiogenesis could be a marker to predict the disease severity of endometrial cancer. Third, the role of functional magnetic resonance imaging (MRI) in endometrial cancer will be elucidated.
Read the detailed description
Adenocarcinoma of the endometrium is the fourth most frequent cancer in women. Surgery is the treatment of choice in patients with noninvasive or locally advanced disease. The surgical technique consists of an exploratory laparotomy, with total hysterectomy, bilateral oophorectomy, peritoneal washing, and, in selected high-risk patients, omental and peritoneal biopsies and lymphadenectomy. Therefore, preoperative clinical and instrumental staging of the local spread of disease, as well as local and distant lymph node involvement, represent a critical step in tailoring the extent and the radicalness of surgery.
The role of angiogenesis in cancer growth and metastasis has been gaining much attention for decades. Recent clinical evidence supports this notion. The gradual increase in angiogenesis intensity with tumor progression in malignant melanoma has been reported. Abulafia et al. observed that increasing angiogenicity from simple hyperplasia, complex hyperplasia, atypical hyperplasia, and Stage IA endometrial carcinoma to invasive endometrial carcinoma has been found by histopathologic examination. Several articles have reported that transvaginal color and pulse Doppler ultrasound may be helpful blood in the evaluation of various gynecologic tumors. Besides, our previous studies have also shown that incremental angiogenesis could be demonstrated in the tumorigenesis and the possibility of lymph node metastasis in endometrial malignancy. Other growth factors such as vascular endothelial growth factor (VEGF), TGF-, IL-6, and IL-8 have also been reported to correlate with the angiogenesis and the metastasis of endometrial cancer. It seems that tumor angiogenesis of endometrial cancer could be utilized as an important parameter to assess the disease severity of the endometrial cancer.
Determining microvessel density is regarded as a standard procedure to quantitate tumor angiogenesis. However, microvessel density always has been assessed retrospectively and in vitro. Preoperative prediction of the microvessel density would be of value clinically for evaluating severity and progression of disease.
So, we would like to propose this proposal to focus on the tumor angiogenesis in endometrial cancer patients. Endometrial cancer patients who will receive staging surgery will be enrolled in this study. Functional MRI, and transvaginal sonography will be undergone before the surgery in each patient. The angiogenesis-related growth factors will be evaluated later from the surgical specimens. The clinical pathologic items, various angiogenic parameters obtained from the MRI and sonography, and angiogenesis-related factors will be compared and correlated together. There are several purposes in this study. First, we will evaluate and compare tumor angiogenesis surveyed from functional MRI and power Doppler sonography in endometrial cancer patients who receive surgery. Second, we will evaluate whether tumor angiogenesis could be a marker to predict the disease severity of endometrial cancer. Third, we will elucidate the role of functional MRI in endometrial cancer.
Endometrial cancer patients with histopathologic proof who are arranged to receive staging surgery are eligible. All patients will undergo surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and/or para-aortic lymph node dissection or sampling. Surgical specimens will be evaluated for tumor size, histologic grading, depth of myometrial invasion, and presence of lymphovascular emboli and lymph node metastasis. Stage will be determined using the International Federation of Gynecology and Obstetrics classification. Tumors of histologic types other than adenocarcinoma and adenoacanthoma will be excluded. The carcinomas were classified using a three-grade system: grade 1 carcinomas showed glandular formation in more than 95% of the tumor, grade 2 carcinomas showed a solid growth pattern in 5-50%, and grade 3 carcinomas showed a solid pattern in more than 50%. All of the patients who will be enrolled into this study need to sign the consent form and the study protocol will be under the approval of the Institutional Review Board of the patient's hospital.
- Conditions
- Endometrial Cancer
- Keywords
- endometrial cancer, MRI, Doppler sonography, angiogenesis
- Medical subject headings
- Endometrial Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2005 (estimated)
- Study startSep 2004
- Study completionDec 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endometrial CancerStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Other
- Enrolment
- 200 participants
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Chi-An Chen, MD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00166985
- Sponsor's protocol ID
- 9361701182
- Status last verified
- Aug 2004
- First submitted
- 12 Sep 2005
- Last updated
- 27 Dec 2006
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Dec 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Functional MRI and Doppler Sonography in Assessing Intratumoral Angiogenesis of Endometrial Cancer Patients
- ClinicalTrials.gov ID
- NCT00166985
- Acronym / sponsor ID
- 9361701182
- Conditions
- Endometrial Cancer
- Keywords
- endometrial cancer, MRI, Doppler sonography, angiogenesis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Sep 2004
- Study completion
- Dec 2008
- First posted
- 14 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adenocarcinoma of the endometrium is the fourth most frequent cancer in women. Surgery is the treatment of choice in patients with noninvasive or locally advanced disease. The surgical technique consists of an exploratory laparotomy, with total hysterectomy, bilateral oophorectomy, peritoneal washing, and, in selected high-risk patients, omental and peritoneal biopsies and lymphadenectomy. Therefore, preoperative clinical and instrumental staging of the local spread of disease, as well as local and distant lymph node involvement, represent a critical step in tailoring the extent and the radicalness of surgery.
The role of angiogenesis in cancer growth and metastasis has been gaining much attention for decades. Recent clinical evidence supports this notion. The gradual increase in angiogenesis intensity with tumor progression in malignant melanoma has been reported. Abulafia et al. reported that increasing angiogenicity could be noted from simple hyperplasia, complex hyperplasia, atypical hyperplasia, and Stage IA endometrial carcinoma to invasive endometrial carcinoma. The investigators' research team has shown that incremental angiogenesis could be demonstrated in the tumorigenesis and the possibility of lymph node metastasis in endometrial malignancy. Besides, other growth factors such as vascular endothelial growth factor (VEGF), transforming growth factor- (TGF-), IL-6 and IL-8 have also been reported to correlate with the angiogenesis and the metastasis of endometrial cancer. It seems that tumor angiogenesis of endometrial cancer could be utilized as an important parameter to assess the disease severity of the endometrial cancer.
So, the investigators would like to propose this proposal to focus on the tumor angiogenesis in endometrial cancer patients. There are several purposes in this study. First, the investigators will evaluate and compare tumor angiogenesis surveyed from functional MRI and power Doppler sonography in endometrial cancer patients who receive surgery. Second, the investigators will evaluate whether tumor angiogenesis could be a marker to predict the disease severity of endometrial cancer. Third, the role of functional magnetic resonance imaging (MRI) in endometrial cancer will be elucidated.
Detailed description
Adenocarcinoma of the endometrium is the fourth most frequent cancer in women. Surgery is the treatment of choice in patients with noninvasive or locally advanced disease. The surgical technique consists of an exploratory laparotomy, with total hysterectomy, bilateral oophorectomy, peritoneal washing, and, in selected high-risk patients, omental and peritoneal biopsies and lymphadenectomy. Therefore, preoperative clinical and instrumental staging of the local spread of disease, as well as local and distant lymph node involvement, represent a critical step in tailoring the extent and the radicalness of surgery.
The role of angiogenesis in cancer growth and metastasis has been gaining much attention for decades. Recent clinical evidence supports this notion. The gradual increase in angiogenesis intensity with tumor progression in malignant melanoma has been reported. Abulafia et al. observed that increasing angiogenicity from simple hyperplasia, complex hyperplasia, atypical hyperplasia, and Stage IA endometrial carcinoma to invasive endometrial carcinoma has been found by histopathologic examination. Several articles have reported that transvaginal color and pulse Doppler ultrasound may be helpful blood in the evaluation of various gynecologic tumors. Besides, our previous studies have also shown that incremental angiogenesis could be demonstrated in the tumorigenesis and the possibility of lymph node metastasis in endometrial malignancy. Other growth factors such as vascular endothelial growth factor (VEGF), TGF-, IL-6, and IL-8 have also been reported to correlate with the angiogenesis and the metastasis of endometrial cancer. It seems that tumor angiogenesis of endometrial cancer could be utilized as an important parameter to assess the disease severity of the endometrial cancer.
Determining microvessel density is regarded as a standard procedure to quantitate tumor angiogenesis. However, microvessel density always has been assessed retrospectively and in vitro. Preoperative prediction of the microvessel density would be of value clinically for evaluating severity and progression of disease.
So, we would like to propose this proposal to focus on the tumor angiogenesis in endometrial cancer patients. Endometrial cancer patients who will receive staging surgery will be enrolled in this study. Functional MRI, and transvaginal sonography will be undergone before the surgery in each patient. The angiogenesis-related growth factors will be evaluated later from the surgical specimens. The clinical pathologic items, various angiogenic parameters obtained from the MRI and sonography, and angiogenesis-related factors will be compared and correlated together. There are several purposes in this study. First, we will evaluate and compare tumor angiogenesis surveyed from functional MRI and power Doppler sonography in endometrial cancer patients who receive surgery. Second, we will evaluate whether tumor angiogenesis could be a marker to predict the disease severity of endometrial cancer. Third, we will elucidate the role of functional MRI in endometrial cancer.
Endometrial cancer patients with histopathologic proof who are arranged to receive staging surgery are eligible. All patients will undergo surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and/or para-aortic lymph node dissection or sampling. Surgical specimens will be evaluated for tumor size, histologic grading, depth of myometrial invasion, and presence of lymphovascular emboli and lymph node metastasis. Stage will be determined using the International Federation of Gynecology and Obstetrics classification. Tumors of histologic types other than adenocarcinoma and adenoacanthoma will be excluded. The carcinomas were classified using a three-grade system: grade 1 carcinomas showed glandular formation in more than 95% of the tumor, grade 2 carcinomas showed a solid growth pattern in 5-50%, and grade 3 carcinomas showed a solid pattern in more than 50%. All of the patients who will be enrolled into this study need to sign the consent form and the study protocol will be under the approval of the Institutional Review Board of the patient's hospital.
Study design
- Observational model
- Defined population
- Time perspective
- Other
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Endometrial cancer patients with histopathologic proof who are arranged to receive staging surgery.
- All of the patients who will be enrolled into this study need to sign the consent form and the study protocol will be under the approval of the Institutional Review Board of the patient's hospital.
Key exclusion criteria (1 listed)
- Tumors of histologic types other than adenocarcinoma and adenoacanthoma will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Dec 2006.
Related trials for Endometrial Cancer
Active, not recruitingPhase 3
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Endometrial Cancer
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 3
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chi-An Chen, MD principal investigator
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endometrial Cancer, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Dec 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chi-An Chen, MD (886-2-2312-3456 ext. 5157, cachen@ha.mc.ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Dec 2006; AzTrials last refreshed its copy on 8 Nov 2026.